Bard PowerPort catheter lawsuit MDL 3081: where the litigation actually stands as bellwether trials begin

The Bard PowerPort litigation has moved from procedural development to active bellwether trials. MDL 3081 (In re: Bard Implanted Port Catheter Products Liability Litigation), centralized in the U.S. District Court for the District of Arizona before Judge David G. Campbell, consolidates approximately 3,044 federal cases as of April 2026, a increase from approximately 1,300 cases at end of 2024. Judge Campbell previously presided over the Bard IVC filter MDL (peaked at 8,000+ claims, settled in stages) and brings substantial mass tort experience to the PowerPort litigation. Bard, Inc. and parent company Becton, Dickinson and Company (BD).

Two recent procedural developments substantially affect the litigation's trajectory. On March 5, 2026, Judge Campbell denied nearly all of Bard's summary judgment motions, a significant win for plaintiffs heading into bellwether trials. The denial preserved plaintiffs' design defect claims, failure-to-warn theories, and most other case theories. On April 21, 2026, the first bellwether trial began: Cook v. Becton Dickinson, an infection case where the catheter allegedly failed within a month of implantation. Five more bellwether trials are scheduled through early 2027, covering different injury types across the various PowerPort product lines (polyurethane, Groshong, and silicone devices).

The theory in the litigation focuses on material defects in the catheter components. Plaintiffs allege the polyurethane and barium sulfate material composition causes catheters to fracture and migrate inside patients. A key procedural issue is Bard's reliance on the FDA 510(k) clearance process, which allowed PowerPort to enter the market in 1999 without clinical testing for long-term safety or durability. Plaintiffs argue that 510(k) clearance doesn't immunize manufacturers from product liability claims when the cleared product proves defective in clinical use. The PowerPort devices have been subject to prior FDA recalls, including the PowerPort duo M.R.I. recall on March 25, 2021 (catheter component issues) and a PowerPort devices recall on October 1, 2019 (component mismatch concerns), supporting plaintiffs' theory that Bard had material knowledge of problems before the litigation.

What are PowerPort catheters and what is the alleged defect?

PowerPort catheters are surgically implanted port devices made by C.R. Bard that provide long-term intravenous access, primarily for chemotherapy. Plaintiffs allege the polyurethane and barium sulfate material composition is structurally unstable, causing catheters to fracture and release fragments that migrate through the vascular system, posing serious health risks to patients.

Implanted port catheters provide long-term vascular access:

Device purpose. PowerPort and similar implanted port catheters serve as long-term intravenous access points for:

• Chemotherapy delivery to cancer patients
• Frequent blood draws or IV medication administration
• Other situations requiring sustained vascular access

The devices are surgically implanted under the skin (typically in the chest wall) with a catheter threaded into a large vein. Medical professionals access the port through needle punctures rather than repeated peripheral IV sticks.

Material composition issue. PowerPort catheters use polyurethane material mixed with barium sulfate (which makes the catheter visible on imaging).

• The polyurethane-barium sulfate composition is structurally unstable
• The material degrades when exposed to chemotherapy drugs and other infusions
• Microscopic cracks develop over time
• The cracks propagate into fractures
• Fractures release fragments that migrate through the vascular system

Specific products implicated. The MDL covers multiple Bard port catheter product lines:

• PowerPort duo M.R.I.
• Various older Bard port catheter products

Internal corporate knowledge. Discovery in MDL 3081 has produced internal Bard documents about the polyurethane-barium sulfate composition issues. The 2019 and 2021 FDA recalls support plaintiffs' theory that Bard had information about device problems before initiating the recalls.

What injuries are alleged in the Bard PowerPort lawsuit?

Plaintiffs in MDL 3081 allege catheter fracture, fragment migration to the heart or pulmonary arteries, bloodstream infections progressing to sepsis, deep vein thrombosis, vascular injury, and the need for surgical device removal. Cancer patients receiving chemotherapy comprise the largest plaintiff population and face compounded health risks from device failure.

Catheter fracture. The catheter portion breaks while inside the body.

Fragment migration. Broken catheter pieces migrate through the vascular system to:

Bloodstream infections (sepsis). Bacterial infection of the catheter:

• Difficult to treat with antibiotics alone
• Can progress to systemic sepsis

Deep vein thrombosis (DVT). Blood clot formation related to catheter presence:

Vascular injury and laceration. Physical damage to blood vessels:

Need for surgical removal. Damaged or infected devices often require:

• Replacement with alternative access method
• Sometimes complicated extraction due to fibrin encapsulation
• Vascular surgery for migrated fragments

Population especially affected. Cancer patients comprise the largest plaintiff population. The devices were specifically used for chemotherapy delivery, exposing patients with already compromised health to additional medical complications from device failure. Some plaintiffs died during the litigation, including second bellwether plaintiff Wanda Miller, who died February 2, 2026, before her scheduled July 7 trial date.

What is the procedural history of MDL 3081?

MDL 3081 was established in August 2023 in the District of Arizona before Judge David G. Campbell. The case count has grown to approximately 3,044 federal cases as of April 2026. The first bellwether trial (Cook v. Becton Dickinson, an infection case) began April 21, 2026, with five more bellwether trials scheduled through early 2027.

Pre-2023. Federal PowerPort lawsuits filed across various district courts. Plaintiffs' attorneys recognized common factual and legal issues.

August 8, 2023. Judicial Panel on Multidistrict Litigation issued transfer order consolidating cases. MDL 3081 established in District of Arizona before Judge David G. Campbell.

Plaintiff Fact Sheet (PFS) framework established covering 8 key areas: personal/claim background, medical history, health insurance, previous claims, witness information, document identification, and document requests.

Throughout 2025. Case count grew from approximately 1,300 to over 2,500 by year-end. More than 1,000 new cases filed in 2025 alone, more than doubling the case count from 2024.

Six trials scheduled May 2026 through February 2027.

January 2026. Federal court preparations for bellwether trials continued.

February 2, 2026. Second bellwether plaintiff Wanda Miller died. Her July 7, 2026 trial date was placed under review.

March 5, 2026. Judge Campbell denied nearly all of Bard's summary judgment motions, significant procedural win for plaintiffs.

April 21, 2026.FIRST BELLWETHER TRIAL BEGAN. Cook v. Becton Dickinson, an infection case where catheter allegedly failed within a month of implantation.

• Second bellwether: July 7, 2026 (under review due to plaintiff death)
• Third bellwether: October 13, 2026
• Fourth bellwether: December 1, 2026
• Fifth bellwether: February 2, 2027
• Sixth bellwether: additional 2027 date

The diversity reflects the court's intent to test liability theories across distinct failure modes rather than concentrating on a single injury profile.

Does FDA 510(k) clearance protect Bard from PowerPort lawsuits?

No. Judge Campbell's March 2026 ruling denied Bard's summary judgment motions, holding that 510(k) clearance does not bar state product liability claims. The U.S. Supreme Court held in Medtronic v. Lohr that 510(k) clearance, unlike full premarket approval (PMA), does not preempt state law product liability claims against medical device manufacturers.

A central procedural issue is Bard's reliance on FDA 510(k) clearance:

510(k) clearance process. Under 21 U.S.C. §360(k) and FDA regulations, medical devices can be cleared for market through demonstration of equivalence" to existing devices rather than full safety testing through premarket approval (PMA) process.

• Doesn't require clinical testing for safety
• Doesn't establish long-term durability
• Used for devices considered similar to existing market products

PowerPort 510(k) history. PowerPort received FDA 510(k) clearance in 1999 without clinical testing for long-term safety or durability. Bard argued in summary judgment motions that 510(k) clearance preempts state product liability claims and immunizes the company from liability.

• 510(k) clearance doesn't establish device safety
• The U.S. Supreme Court has held in Medtronic v. Lohr that 510(k) clearance doesn't preempt state product liability claims (the PMA process can preempt under Riegel v. Medtronic, but 510(k) doesn't have the same effect)
• Bard prioritized market speed over patient safety
• The 510(k) framework doesn't establish that PowerPort is actually safe

Judge Campbell's denial of summary judgment. The March 2026 ruling preserved plaintiffs' claims, accepting that 510(k) clearance doesn't bar product liability claims when the cleared device proves defective in clinical use. The ruling supports plaintiffs heading into bellwether trials.

Who is eligible to file a Bard PowerPort lawsuit?

Eligibility requires documented implantation of a Bard PowerPort or similar Bard port catheter, a qualifying injury such as catheter fracture, infection, deep vein thrombosis, or vascular injury, and a temporal relationship between device use and injury. Most states impose a 2 to 3 year statute of limitations from injury or discovery of the device failure.

Documented PowerPort implantation. Records showing the claimant received a Bard PowerPort or similar Bard port catheter:

• Operative report from implantation surgery

• Implant card or device identification

• Hospital records identifying the specific Bard product

• Catheter fracture (with or without fragment migration)

• Fragment migration requiring surgical retrieval

• Deep vein thrombosis or pulmonary embolism related to device

• Need for emergency removal or surgical intervention

Temporal relationship. The injury developed during or after PowerPort use. Cases with strong temporal connection between device implantation and injury are typically stronger than cases with substantial time gaps and multiple alternative explanations.

• Subsequent medical records showing complications
• Imaging studies showing fracture, migration, or other device problems
• Treatment records for complications (infection treatment, anticoagulation, etc.)
• Pathology reports for retrieved fragments

Statute of limitations analysis. State-specific limitations periods apply. Most states have 2-3 years from injury or discovery. The discovery rule applies in many jurisdictions: limitations begins when the patient knew or should have known about device failure, not at implantation. Cases involving recent complications often qualify for discovery rule extension even when the original device was implanted years ago.

Fibrin encapsulation challenge. Long-implanted devices often develop fibrin encapsulation around the catheter.

• Hide signs of catheter fracture from imaging
• Complicate forensic evidence during removal
• Delay diagnosis of device failure
• Affect statute of limitations analysis (discovery rule application)

Fragment retrieval and pathology examination can establish device failure even when the encapsulation made detection difficult.

What are the expected settlement amounts in the Bard PowerPort lawsuit?

Severe cases involving permanent disability or wrongful death may substantially exceed typical ranges. Final values depend on bellwether trial outcomes running through early 2027.

Infection-only cases. Tens of thousands of dollars typical, depending on:

Fracture cases with migration and vascular injury. Hundreds of thousands of dollars typical:

• Wrongful death claims for deceased plaintiffs
• Specific factual circumstances strengthening cases

Becton Dickinson's substantial capacity. BD has financial capacity for settlement (similar to Bard hernia mesh MDL 2846 where BD's multi-billion dollar settlement framework resolved approximately 38,000 claims). The corporate structure suggests resolution capacity exists for settlement.

Tax implications for settlement recipients. Personal injury settlements for physical injuries are generally tax-free under IRC §104(a)(2). But specific components (punitive damages, interest, certain emotional distress damages without physical injury) may be taxable. Coordination with tax counsel before accepting settlements is appropriate, particularly when tax debt forgiveness or other tax issues are involved.

How does the PowerPort lawsuit compare to other ongoing mass torts?

The PowerPort litigation shares features with other Bard/BD mass torts but is in an earlier bellwether phase. Compared to the Bard hernia mesh MDL ($1+ billion settlement) and other device MDLs, PowerPort has strong theories, a financially capable defendant, and active bellwether trials that will shape its resolution trajectory over the next two to four years.

The broader procedural framework for mass tort settlements is detailed in our overview of how mass tort litigation works. PowerPort represents an active, growing mass tort with bellwether trial activity that will determine ultimate resolution framework.

What strategic considerations should PowerPort plaintiffs know?

File claims promptly. Statute of limitations periods are running. The discovery rule provides some flexibility, but cases involving older implantations and recent symptoms benefit from prompt evaluation. Most states have 2-3 year limitations periods from injury or discovery.

Engage experienced mass tort counsel. The MDL is procedurally specific and benefits from counsel with established PowerPort case experience. Most plaintiffs' firms work on contingency basis (typically 30-40% of recovery). Search PACER for plaintiff's counsel experience in the litigation if researching attorneys.

Document the medical timeline comprehensively. The strongest cases include:

• Original PowerPort implantation operative report
• Device identification (specific model, lot number when available)
• Complete medical records following implantation
• Documentation of complications and their development
• Imaging studies showing fracture or migration
• Pathology reports for retrieved fragments

Watch the bellwether trial outcomes. The six bellwether trials through early 2027 will substantially affect settlement framework. Monitor outcomes through legal news sources or counsel updates. Trial outcomes affect both case-specific viability and overall settlement leverage.

Address fibrin encapsulation documentation carefully. When device is removed, pathology examination of retrieved components is important for establishing fracture or material degradation. Coordinate with treating physicians about preserving evidence during device removal.

Don't accept inadequate pre-bellwether settlements. Some firms may offer early settlements before bellwether outcomes substantially affect pricing. Have any settlement offer evaluated by counsel familiar with current litigation dynamics.

Coordinate with treating physicians. Oncologists, infectious disease specialists, vascular surgeons, and other treating physicians are important witnesses. Their support for the case theory and connection to PowerPort device strengthens cases substantially.

Consider wrongful death framework for deceased plaintiffs. Estates of deceased plaintiffs (including those who died during the litigation like second bellwether plaintiff Wanda Miller) can pursue wrongful death claims with separate procedural framework.

Tax planning for settlements. Settlement allocation between physical injury (tax-free under §104(a)(2)) and other components (potentially taxable) requires careful structuring. Coordinate with tax counsel familiar with personal injury settlement structuring, particularly when other tax issues like NFTL withdrawals or Voluntary Disclosure Practice considerations exist.

Watch for state court alternatives. Some plaintiffs may benefit from state court filings rather than federal MDL participation. The procedural analysis depends on state-specific factors and case characteristics.

Cancer patient considerations. PowerPort plaintiffs often have ongoing oncological treatment needs. Don't let case management interfere with active cancer treatment. Legal counsel familiar with cancer patient situations handles these cases more sensitively.

The Bard PowerPort litigation represents a mass tort with strong case theory, procedural momentum heading into bellwether trials, and a financially-capable defendant that can fund eventual global settlement. The combination of Judge Campbell's denial of Bard's summary judgment motions, the active bellwether trial schedule running through early 2027, and the cancer patient demographic creates conditions for meaningful resolution within the next 2-4 years. The case theory, that polyurethane-barium sulfate composition causes catheter fracture and migration, has survived motion practice and is now being tested before juries. For affected patients with documented PowerPort complications, the framework provides paths to compensation that recognize the serious harm caused by device failures in already-vulnerable cancer patient populations. The work for plaintiffs is in comprehensive medical documentation, engagement with experienced counsel familiar with the MDL framework, patient navigation of the extended bellwether timeline, and informed evaluation of settlement opportunities as bellwether outcomes affect the settlement landscape. For plaintiffs with strong documentation and serious injuries, the eventual resolution should produce meaningful compensation for medical costs, lost wages, pain and suffering, and the quality of life impact caused by the alleged catheter defects.